Literature DB >> 27534750

Neuropsychiatric Effects of HIV Antiviral Medications.

Glenn J Treisman1,2, Olivia Soudry3,4.   

Abstract

The development of antiretroviral therapy (ART) has dramatically increased the lifespan of HIV patients but treatment is complicated by numerous adverse effects and toxicities. ART complications include neuropsychiatric, metabolic, gastrointestinal, cardiac, and numerous other toxicities, and clinicians often have to choose one toxicity over another to offer the best medication regimen for a patient. Some antiviral drugs cause significant neuropsychiatric complications, including depression, cognitive impairment, and sleep disturbance. Even in careful studies, it may be difficult to determine which effects are related to the virus, the immune system, or the treatment. Of the six currently marketed classes of antiviral drugs, the nucleoside reverse transcriptase inhibitors and the non-nucleoside reverse transcriptase inhibitors have been most commonly associated with neuropsychiatric complications. Within these classes, certain drugs are more likely to cause difficulty than others. We review the contention regarding the central nervous system (CNS) complications of efavirenz, as well as debate about the role of CNS penetration in drug effectiveness and toxicity. A thorough working knowledge of the neuropsychiatric consequences of ART allows clinicians to tailor treatment more successfully to individual patients as well as to identify ART more quickly as the source of a problem or symptom.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27534750     DOI: 10.1007/s40264-016-0440-y

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  123 in total

1.  Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.

Authors:  Jacqueline A Pettersen; Gareth Jones; Catherine Worthington; Hartmut B Krentz; Oliver T Keppler; Ahmet Hoke; M John Gill; Christopher Power
Journal:  Ann Neurol       Date:  2006-05       Impact factor: 10.422

2.  Rilpivirine and Depression.

Authors:  David Freeman; James Levenson
Journal:  Psychosomatics       Date:  2015-06-06       Impact factor: 2.386

3.  Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.

Authors:  Katrina Pollock; Justin Stebbing; Mark Bower; Brian Gazzard; Mark Nelson
Journal:  J Antimicrob Chemother       Date:  2006-05-09       Impact factor: 5.790

4.  Severe insomnia related to high concentrations of raltegravir.

Authors:  Céline Eiden; Hélène Peyriere; Gilles Peytavin; Jacques Reynes
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

5.  Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.

Authors:  Markus Bickel; Christoph Stephan; Carsten Rottmann; Amina Carlebach; Anette Haberl; Michael Kurowski; Schlomo Staszewski
Journal:  Scand J Infect Dis       Date:  2005

6.  Exacerbation of peripheral neuropathy by lamivudine.

Authors:  E J Cupler; M C Dalakas
Journal:  Lancet       Date:  1995-02-18       Impact factor: 79.321

7.  Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.

Authors:  Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

8.  Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.

Authors:  E Pedrol; J M Llibre; M Tasias; A Currán; J M Guardiola; E Deig; A Guelar; O Martínez-Madrid; L Tikhomirova; R Ramírez
Journal:  HIV Med       Date:  2015-08-04       Impact factor: 3.180

9.  Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient.

Authors:  Marcel Lee; Florian Eyer; Norbert Felgenhauer; Hartwig Hf Klinker; Christoph D Spinner
Journal:  AIDS Res Ther       Date:  2015-05-21       Impact factor: 2.250

10.  Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.

Authors:  Laura Dickinson; Janaki Amin; Laura Else; Marta Boffito; Deirdre Egan; Andrew Owen; Saye Khoo; David Back; Catherine Orrell; Amanda Clarke; Marcelo Losso; Praphan Phanuphak; Dianne Carey; David A Cooper; Sean Emery; Rebekah Puls
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

View more
  16 in total

1.  The dual modulatory effects of efavirenz on GABAA receptors are mediated via two distinct sites.

Authors:  Renqi Huang; Zhenglan Chen; Sean Dolan; John A Schetz; Glenn H Dillon
Journal:  Neuropharmacology       Date:  2017-04-27       Impact factor: 5.250

2.  What Does Aging with HIV Mean for Nursing Homes?

Authors:  Amy C Justice; Kathleen M Akgün
Journal:  J Am Geriatr Soc       Date:  2019-05-07       Impact factor: 5.562

Review 3.  Neuroinflammation in HIV-associated depression: evidence and future perspectives.

Authors:  Arish Mudra Rakshasa-Loots; Heather C Whalley; Jaime H Vera; Simon R Cox
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 13.437

4.  Differential Effects of Antiretroviral Drugs on Neurons In Vitro: Roles for Oxidative Stress and Integrated Stress Response.

Authors:  Anna L Stern; Rebecca N Lee; Nina Panvelker; Jiean Li; Jenna Harowitz; Kelly L Jordan-Sciutto; Cagla Akay-Espinoza
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-31       Impact factor: 4.147

5.  Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.

Authors:  Kelly L Stauch; Katy Emanuel; Benjamin G Lamberty; Brenda Morsey; Howard S Fox
Journal:  J Neurovirol       Date:  2017-09-11       Impact factor: 2.643

6.  Central nervous system (CNS) transcriptomic correlates of human immunodeficiency virus (HIV) brain RNA load in HIV-infected individuals.

Authors:  Pietro Paolo Sanna; Yu Fu; Eliezer Masliah; Celine Lefebvre; Vez Repunte-Canonigo
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.996

Review 7.  CNS Neurotoxicity of Antiretrovirals.

Authors:  Tyler Lanman; Scott Letendre; Qing Ma; Anne Bang; Ronald Ellis
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-10       Impact factor: 4.147

8.  Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.

Authors:  Joseph W George; Jane E Mattingly; Nashanthea J Roland; Cassandra M Small; Benjamin G Lamberty; Howard S Fox; Kelly L Stauch
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

9.  Chemical exchange saturation transfer for detection of antiretroviral drugs in brain tissue.

Authors:  Aditya N Bade; Howard E Gendelman; JoEllyn McMillan; Yutong Liu
Journal:  AIDS       Date:  2021-09-01       Impact factor: 4.632

10.  Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.

Authors:  JoEllyn McMillan; Adam Szlachetka; Lara Slack; Brady Sillman; Benjamin Lamberty; Brenda Morsey; Shannon Callen; Nagsen Gautam; Yazen Alnouti; Benson Edagwa; Howard E Gendelman; Howard S Fox
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.